MX2009006202A - Composiciones y metodos para el tratamiento de neoplasma. - Google Patents
Composiciones y metodos para el tratamiento de neoplasma.Info
- Publication number
- MX2009006202A MX2009006202A MX2009006202A MX2009006202A MX2009006202A MX 2009006202 A MX2009006202 A MX 2009006202A MX 2009006202 A MX2009006202 A MX 2009006202A MX 2009006202 A MX2009006202 A MX 2009006202A MX 2009006202 A MX2009006202 A MX 2009006202A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- compositions
- methods
- neoplasm
- neoplasms
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000035269 cancer or benign tumor Diseases 0.000 title 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87446006P | 2006-12-11 | 2006-12-11 | |
| PCT/US2007/068300 WO2008073509A2 (en) | 2006-12-11 | 2007-05-04 | Compositions and methods for treating a neoplasm |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009006202A true MX2009006202A (es) | 2009-06-22 |
Family
ID=38521756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009006202A MX2009006202A (es) | 2006-12-11 | 2007-05-04 | Composiciones y metodos para el tratamiento de neoplasma. |
Country Status (17)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME02371B (me) | 2006-09-29 | 2016-06-20 | Oncomed Pharm Inc | Sastojci i postupci za dijagnstikovanje i tretman raka |
| US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| WO2012088438A1 (en) * | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| CN107722122B (zh) | 2011-09-23 | 2022-05-27 | 昂考梅德药品有限公司 | Vegf/dll4结合剂及其应用 |
| RU2672553C2 (ru) * | 2012-03-14 | 2018-11-16 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Соединения и способы лечения лейкемии |
| AU2013337811A1 (en) | 2012-10-31 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| GB201409471D0 (en) * | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| PT3212233T (pt) | 2014-10-31 | 2020-07-16 | Oncomed Pharm Inc | Terapia combinada para o tratamento de doenças |
| RU2700696C2 (ru) | 2015-07-27 | 2019-09-19 | Чонг Кун Данг Фармасьютикал Корп. | 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция |
| WO2017018803A1 (en) | 2015-07-27 | 2017-02-02 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| NZ736432A (en) | 2015-07-27 | 2019-01-25 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| HUE057544T2 (hu) | 2015-08-04 | 2022-05-28 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazol-származék vegyületek mint hiszton deacetiláz 6 inhibitorok, és ezeket tartalmazó gyógyszerkészítmények |
| ES2968074T3 (es) | 2015-09-23 | 2024-05-07 | Mereo Biopharma 5 Inc | Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino |
| RU2695133C1 (ru) | 2015-10-12 | 2019-07-22 | Чонг Кун Данг Фармасьютикал Корп. | Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| ES3009668T3 (en) | 2018-01-26 | 2025-03-31 | Univ California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
| KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| EP3976602A4 (en) | 2019-05-31 | 2023-05-31 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF |
| CA3168512A1 (en) | 2019-11-25 | 2021-06-03 | Napoleone Ferrara | Long-acting vegf inhibitors for intraocular neovascularization |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| US6169106B1 (en) * | 1998-04-15 | 2001-01-02 | Boehringer Ingelheim Pharma Kg | Indolinones having kinase inhibitory activity |
| HUP0104973A3 (en) * | 1998-09-25 | 2002-06-28 | Boehringer Ingelheim Pharma | Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes, process for their use and medicaments containing them |
| US6762180B1 (en) * | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
| US6638965B2 (en) * | 2000-11-01 | 2003-10-28 | Boehringer Ingelheim Pharma Kg | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7758859B2 (en) * | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| AR069501A1 (es) * | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
-
2007
- 2007-05-04 EP EP07761925.2A patent/EP2099489B1/en not_active Not-in-force
- 2007-05-04 AU AU2007333565A patent/AU2007333565A1/en not_active Abandoned
- 2007-05-04 WO PCT/US2007/068300 patent/WO2008073509A2/en not_active Ceased
- 2007-05-04 SI SI200731500T patent/SI2099489T1/sl unknown
- 2007-05-04 ZA ZA200903489A patent/ZA200903489B/xx unknown
- 2007-05-04 CA CA002670707A patent/CA2670707A1/en not_active Abandoned
- 2007-05-04 KR KR1020097011980A patent/KR101320198B1/ko not_active Expired - Fee Related
- 2007-05-04 MX MX2009006202A patent/MX2009006202A/es active IP Right Grant
- 2007-05-04 NZ NZ577058A patent/NZ577058A/en not_active IP Right Cessation
- 2007-05-04 BR BRPI0717688-0A patent/BRPI0717688A2/pt not_active IP Right Cessation
- 2007-05-04 DK DK07761925.2T patent/DK2099489T3/da active
- 2007-05-04 CN CN2007800451061A patent/CN101547705B/zh not_active Expired - Fee Related
- 2007-05-04 JP JP2009541425A patent/JP2010512407A/ja active Pending
- 2007-05-04 SG SG2011091626A patent/SG177891A1/en unknown
- 2007-05-04 RU RU2009126588/15A patent/RU2482877C2/ru not_active IP Right Cessation
- 2007-05-04 US US12/518,628 patent/US20100086544A1/en not_active Abandoned
-
2009
- 2009-05-20 IL IL198852A patent/IL198852A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010512407A (ja) | 2010-04-22 |
| NZ577058A (en) | 2012-04-27 |
| RU2482877C2 (ru) | 2013-05-27 |
| SG177891A1 (en) | 2012-02-28 |
| IL198852A (en) | 2013-06-27 |
| EP2099489A2 (en) | 2009-09-16 |
| US20100086544A1 (en) | 2010-04-08 |
| WO2008073509A2 (en) | 2008-06-19 |
| DK2099489T3 (da) | 2014-08-18 |
| CA2670707A1 (en) | 2008-06-19 |
| SI2099489T1 (sl) | 2014-09-30 |
| CN101547705A (zh) | 2009-09-30 |
| ZA200903489B (en) | 2010-08-25 |
| KR101320198B1 (ko) | 2013-10-30 |
| IL198852A0 (en) | 2011-08-01 |
| CN101547705B (zh) | 2013-06-12 |
| KR20090087908A (ko) | 2009-08-18 |
| HK1131064A1 (en) | 2010-01-15 |
| BRPI0717688A2 (pt) | 2013-01-22 |
| WO2008073509A3 (en) | 2009-01-08 |
| AU2007333565A1 (en) | 2008-06-19 |
| EP2099489B1 (en) | 2014-05-21 |
| RU2009126588A (ru) | 2011-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006202A (es) | Composiciones y metodos para el tratamiento de neoplasma. | |
| MX2022009759A (es) | El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea. | |
| MX354099B (es) | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. | |
| TW200744568A (en) | Epinephrine dosing regimens | |
| MY172372A (en) | Compositions and methods for lowering triglycerides | |
| MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
| IL226717A0 (en) | Antibodies@ofpeople@of@@@beta@and their use | |
| MY151191A (en) | Novel antibodies | |
| IN2012DN00572A (cg-RX-API-DMAC7.html) | ||
| MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| GB2466912A (en) | Compositions and methods for treating lysosomal disorders | |
| EA201070059A1 (ru) | Композиции, содержащие ингибиторы триптофангидроксилазы | |
| TW200727920A (en) | New regimens for oral monophasic contraceptives | |
| MX2010008994A (es) | Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario. | |
| TW200700071A (en) | Novel use | |
| ZA200807281B (en) | CCR5 antagonists useful for treating HIV | |
| MX2013008559A (es) | Derivados de leptina. | |
| TN2010000463A1 (en) | Compositions and methods for preparing and using same | |
| UA104730C2 (en) | Isoquinolinone derivatives as nk3 antagonists | |
| MX2010003373A (es) | Moduladores de receptores muscarinicos. | |
| EP1722782A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING OR TREATING HIV-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |